NorthStar Medical Radioisotopes Announces The Signing Of A Strategic Master Supply Agreement With Cellectar Biosciences, Under Which Cellectar Will Acquire And Integrate Northstar's N.c.a. Ac-225 Into Cellectar's Proprietary Phospholipid Ethers...
Express News | Northstar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $7
Positive Buy Rating on Cellectar Biosciences Driven by Promising Iopofosine-131 Results and Strategic Advancements
Cellectar Biosciences Is Maintained at Outperform by Oppenheimer